ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 20.2 | 16.6 | 23.3 |
| Other income | 0.4 | 0.1 | 0.6 |
| Total income | 20.6 | 16.7 | 23.9 |
| Profit before exceptional items & tax | 1.5 | 5.5 | -1.3 |
| Profit before tax | 1.5 | 5.5 | -1.3 |
| Net profit | 1.5 | 5.5 | -1.5 |
| Operating margin | 7.3% | 32.9% | -5.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -72.70% |
|---|---|
| Revenue, year on year | -13.30% |
BSE results filing, NSE: BROOKS. Figures extracted from the filing.
Brooks Laboratories Ltd: key numbers
- Share price
- ₹67.28
- Market cap
- ₹198.2 Cr
- Revenue (annual)
- ₹85.74 Cr
- Net profit (annual)
- ₹24.58 Cr
- P/E (TTM)
- 2.7×Sector 43.8×
- Promoter holding
- 52.62%+0.00% QoQ
- FII holding
- 0.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Brooks Laboratories Ltd
All →Brooks Laboratories Q2 FY27 Results: Net Profit ₹67.6 Cr, Up 745.0% YoY
Brooks Laboratories Ltd reported revenue from operations of ₹19.2 Cr (-18.3% YoY) and net profit of ₹67.6 Cr (+745.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹67.6 Cr · +745.0% YoY
Brooks Laboratories Board Meeting Date
Brooks Laboratories will hold a board meeting on 7 November 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. The trading window is closed until 9 November 2026.
Brooks Laboratories Other Announcement
Brooks Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI regulatory requirements.
Brooks Laboratories Merger & Restructuring
Brooks Laboratories approved a demerger of its Manufacturing Business into its wholly-owned subsidiary, Abridge Speciality Limited, through a scheme of arrangement.
Brooks Laboratories Price Movement Clarification
Brooks Laboratories informed BSE it has no additional material information to disclose regarding the recent price movement. The company attributed the share price and volume changes to purely market-driven factors.
Brooks Laboratories Management Change
Brooks Laboratories Ltd announced the resignation of Ms. Krutika Rane, Company Secretary and Compliance Officer, effective October 9, 2026.